ATE302017T1 - Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden - Google Patents

Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden

Info

Publication number
ATE302017T1
ATE302017T1 AT01272599T AT01272599T ATE302017T1 AT E302017 T1 ATE302017 T1 AT E302017T1 AT 01272599 T AT01272599 T AT 01272599T AT 01272599 T AT01272599 T AT 01272599T AT E302017 T1 ATE302017 T1 AT E302017T1
Authority
AT
Austria
Prior art keywords
defects
treatment
composition
damage caused
tissue damage
Prior art date
Application number
AT01272599T
Other languages
English (en)
Inventor
Acosta Jorge Berlanga
Nieto Gerardo E Linea Guillen
Del Barco Herrera Diana Garcia
Masso Julio Raul Fernandez
Garcia Mario Pablo Estrada
Perez Isabel Guillen
Alba Jose Suarez
Rodriguez Rebeca Martinez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of ATE302017T1 publication Critical patent/ATE302017T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01272599T 2001-01-03 2001-12-17 Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden ATE302017T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20010005A CU23157A1 (es) 2001-01-03 2001-01-03 COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
PCT/CU2001/000013 WO2002053167A2 (es) 2001-01-03 2001-12-17 Combinacion farmaceutica para el tratamiento del dano tisular debido a falta de irrigacion sanguinea arterial

Publications (1)

Publication Number Publication Date
ATE302017T1 true ATE302017T1 (de) 2005-09-15

Family

ID=40091523

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01272599T ATE302017T1 (de) 2001-01-03 2001-12-17 Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden

Country Status (20)

Country Link
US (1) US7361638B2 (de)
EP (1) EP1354597B1 (de)
JP (2) JP4181875B2 (de)
KR (1) KR100839857B1 (de)
CN (1) CN1247256C (de)
AR (1) AR032217A1 (de)
AT (1) ATE302017T1 (de)
AU (1) AU2002216897A1 (de)
BR (1) BRPI0108882B8 (de)
CA (2) CA2398983C (de)
CU (1) CU23157A1 (de)
DE (1) DE60112807T2 (de)
DK (1) DK1354597T3 (de)
EA (2) EA006036B1 (de)
ES (1) ES2248229T3 (de)
MX (1) MXPA02008667A (de)
MY (1) MY129079A (de)
SI (1) SI1354597T1 (de)
WO (1) WO2002053167A2 (de)
ZA (1) ZA200206954B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005111253A (ru) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) Аналоги ghrh
EP1684786A4 (de) * 2003-10-24 2007-12-12 Merck & Co Inc Verbessertung der spiegel des wachstumshormons mit einem dipeptidyl-peptidase-iv-hemmer und einem wachstumshormon-sekretagog
EP1529533A1 (de) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Behandlung von ischämischen Gehirnschäden mit Wachstumshormon-Sekretionsförderern
AU2004298299A1 (en) * 2003-12-16 2005-06-30 University Technologies International Inc. A treatment for necrotizing enterocolitis
CU23529A1 (es) * 2005-03-02 2010-06-17 Ct Ingenieria Genetica Biotech Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune
CU23389B6 (es) * 2005-12-29 2009-07-16 Ct Ingenieria Genetica Biotech Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica
CU23592A1 (es) * 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
CU23526B6 (es) 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
RU2328288C1 (ru) * 2007-02-21 2008-07-10 ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ лечения трофических язв нижних конечностей при посттромботической болезни
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US8093213B2 (en) * 2007-04-30 2012-01-10 Nationwide Children's Hospital, Inc. Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation
PL3338791T3 (pl) * 2008-07-17 2020-04-30 Acorda Therapeutics, Inc. Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
WO2014152906A2 (en) 2013-03-14 2014-09-25 Research Institute At Nationwide Children's Hospital, Inc. Tissue engineered intestine
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR102733066B1 (ko) 2015-06-26 2024-11-21 주식회사 파마리서치 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물
WO2017087754A2 (en) * 2015-11-18 2017-05-26 President And Fellows Of Harvard College Compositions and methods of mechanically inducing tissue regeneration
CU24591B1 (es) * 2018-08-21 2022-04-07 Ct Ingenieria Genetica Biotecnologia Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento
WO2020038499A1 (es) 2018-08-21 2020-02-27 Centro De Ingeniería Genética Y Biotecnología Uso del ghrp-6 como cardioprotector y cardiorestaurador tardio
CN109908331A (zh) * 2019-04-30 2019-06-21 青岛大学附属医院 海沙瑞林在制备保护肾脏缺血再灌注损伤药物/药物组合物中的应用
WO2025242247A1 (es) 2024-05-21 2025-11-27 Centro De Ingeniería Genética Y Biotecnología Uso del péptido ghrp-6 para el tratamiento de la senescencia y la cicatrización de heridas crónicas complejas refractarias

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5360790A (en) * 1990-12-11 1994-11-01 The Regents Of The University Of Michigan Method and formulations for the therapy of acute renal failure
KR970032600A (ko) 1995-12-30 1997-07-22 배순훈 전기압력보온밥솥용 압력센싱장치의 이상 발생인식방법
SE9703929D0 (sv) 1996-11-22 1997-10-28 Pharmacia & Upjohn Ab Therapeutical use and method
KR100226985B1 (ko) * 1997-07-14 1999-10-15 윤재승 신규한 인간성장호르몬방출인자-인간상피세포성장인자 융합유전자, 이의 발현벡터 및 이를 이용한 인간성장호르몬방출인자의 제조방법
US6191109B1 (en) * 1997-10-31 2001-02-20 Children's Hospital, Inc. Methods of treating intestinal ischemia using heparin-binding epidermal growth factor
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
CA2341649A1 (en) 1998-09-02 2000-03-09 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
CN1244561C (zh) * 2000-05-11 2006-03-08 布里斯托尔-迈尔斯斯奎布公司 可用作生长激素促分泌素的四氢异喹啉类似物
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
SK287169B6 (sk) * 2000-06-13 2010-02-08 Zentaris Ag Zlúčeniny zvyšujúce sekréciu rastového hormónu, farmaceutický prostriedok s ich obsahom a ich použitie

Also Published As

Publication number Publication date
EA006036B1 (ru) 2005-08-25
JP4958844B2 (ja) 2012-06-20
MXPA02008667A (es) 2003-03-27
BRPI0108882B8 (pt) 2021-05-25
KR100839857B1 (ko) 2008-06-19
MY129079A (en) 2007-03-30
ES2248229T3 (es) 2006-03-16
JP2004516332A (ja) 2004-06-03
AR032217A1 (es) 2003-10-29
SI1354597T1 (sl) 2006-02-28
CU23157A1 (es) 2006-07-18
US7361638B2 (en) 2008-04-22
EA007466B1 (ru) 2006-10-27
ZA200206954B (en) 2003-12-01
EA200500646A1 (ru) 2005-10-27
DK1354597T3 (da) 2005-12-19
JP2008231121A (ja) 2008-10-02
WO2002053167A3 (es) 2002-11-14
CA2789161A1 (en) 2002-07-11
DE60112807T2 (de) 2006-06-29
BR0108882A (pt) 2003-04-29
CN1407899A (zh) 2003-04-02
HK1053428A1 (en) 2003-10-24
CA2398983A1 (en) 2002-07-11
US20030186865A1 (en) 2003-10-02
CN1247256C (zh) 2006-03-29
DE60112807D1 (de) 2005-09-22
AU2002216897A1 (en) 2002-07-16
EP1354597A2 (de) 2003-10-22
EP1354597B1 (de) 2005-08-17
EA200200850A1 (ru) 2003-02-27
CA2789161C (en) 2015-04-07
BRPI0108882B1 (pt) 2016-06-14
WO2002053167A2 (es) 2002-07-11
JP4181875B2 (ja) 2008-11-19
KR20030001370A (ko) 2003-01-06
CA2398983C (en) 2012-11-20

Similar Documents

Publication Publication Date Title
ATE302017T1 (de) Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE60335560D1 (de) Zusammensetzungen enthaltend zitronensäure zur behandlung von nagelpilzerkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE602005002930D1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60311822D1 (de) Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1354597

Country of ref document: EP